CeQur has presented initial data from a clinical study of its PaQ insulin delivery device, designed for use in patients with type 2 diabetes.
Comprising a disposable insulin infuser reservoir attached to a reusable insulin monitor, the discreet, wearable CE-marked device provides three days of consistent, basal insulin delivery along with on-demand bolus insulin.
The study, which enrolled 20 patients, is evaluating the ability of people with type 2 diabetes who were on a stable multiple daily insulin injections (MDI) regimen to use PaQ to replace the daily insulin injections required to control the blood sugar.
Approximately 50% of insulin-requiring individuals do not achieve appropriate glycemic control, which is associated with additional healthcare costs and high risk of disabling complications including diabetic retinopathy, chronic kidney and cardiovascular diseases, according to the company.
Glycemic control, patient satisfaction and safety are the endpoints of the study.
Medical University of Graz endocrinology and metabolism division member Dr Julia Mader, who presented the data, said; "This study demonstrated that simple infusion with a device such as PaQ is a valid approach for people with type 2 diabetes who are dependent on multiple daily insulin injections."
The study also demonstrated that PaQ safely and effectively delivered patients' insulin requirements with a high level of patient satisfaction and acceptance.
In addition, no severe hypoglycemic events occurred during the study baseline period, or while participants were using the PaQ device.
The data was presented at the 6th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Paris, France.